A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells

J Am Coll Cardiol. 2006 May 2;47(9):1786-95. doi: 10.1016/j.jacc.2005.11.081. Epub 2006 Apr 19.

Abstract

Objectives: Novel stents loaded with an integrin-binding cyclic Arg-Gly-Asp peptide (cRGD) were analyzed for their potential to limit coronary neointima formation and to accelerate endothelialization by attracting endothelial progenitor cells (EPCs).

Background: Re-endothelialization is important for healing after arterial injury.

Methods: Effects of cRGD on EPC number, recruitment in flow, and invasion were analyzed in vitro. A durable polymer coating containing 67 microg cRGD per stent was developed for Guidant Tetra stents. Twelve cRGD-loaded polymer, 12 unloaded polymer, and 12 bare metal stents were deployed in porcine coronary arteries. Quantification of cRGD in peri-stent tissue was established by high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Histomorphometry and immunostaining were performed after 4 and 12 weeks. Recruitment of labeled porcine EPCs was assessed 7 days after intracoronary infusion.

Results: The cRGD clearly supported the outgrowth, recruitment, and migration of EPCs in vitro. At 4 weeks, there was no difference for mean neointimal area and percent area stenosis in the cRGD-loaded, polymer, or bare metal stent group. At 12 weeks, neointimal area (2.2 +/- 0.3 mm2) and percent area stenosis (33 +/- 5%) were significantly reduced compared with polymer stents (3.8 +/- 0.4 mm2, 54 +/- 6%; p = 0.010) or bare metal stents (3.8 +/- 0.3 mm2, 53 +/- 3%; p < 0.001). The HPLC/MS confirmed cRGD tissue levels of 1 to 3 mug/stent at 4 weeks, whereas cRGD was not detectable at 12 weeks. Staining for CD34 and scanning electron microscopy indicated enhanced endothelial coverage on cRGD-loaded stents at 4 weeks associated with a significant increase in the early recruitment of infused EPCs.

Conclusions: Stent coating with cRGD may be useful for reducing in-stent restenosis by accelerating endothelialization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Adhesion
  • Cell Movement / drug effects*
  • Cells, Cultured
  • Coated Materials, Biocompatible
  • Coronary Restenosis / prevention & control
  • Coronary Vessels / pathology*
  • Endothelial Cells / cytology*
  • Endothelial Cells / drug effects
  • Endothelial Cells / physiology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / physiopathology
  • Hyperplasia
  • Peptides, Cyclic / pharmacokinetics
  • Peptides, Cyclic / pharmacology*
  • Stem Cells / cytology*
  • Stem Cells / drug effects
  • Stem Cells / physiology
  • Stents*
  • Swine
  • Tunica Intima / drug effects*
  • Tunica Intima / pathology

Substances

  • Coated Materials, Biocompatible
  • Peptides, Cyclic
  • cyclic arginine-glycine-aspartic acid peptide